by EpicentRx | Mar 18, 2015 | Conferences
March 2015, Düsseldorf, Germany Abstract: Early results from a phase 2 study of RRx-001, a novel epigenetic modulator, show resensitization to irinotecan in colorectal cancer
by EpicentRx | Mar 18, 2015 | Conferences
March 2015, Seville, Spain Invited Presentation: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
by EpicentRx | Feb 18, 2015 | Conferences
February 2015, San Francisco, California Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study
by EpicentRx | Feb 18, 2015 | Conferences
Feb 2015, La Jolla, California Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the phase 2 “ROCKET” study
by EpicentRx | Oct 18, 2014 | Conferences
October 2014, San Diego, California Abstract: RRx-001 an EXO-based epigenetic anti-cancer agent in phase 2 clinical trials
